论文部分内容阅读
目的分析参芪化瘀解毒方在手术联合肝动脉化疗栓塞术(TACE)治疗原发性肝癌患者中的作用。方法选取医院收治的76例原发性肝癌患者为研究对象,随机分为观察组和对照组,每组38例。对照组采用肝癌切除术联合TACE进行治疗,观察组在对照组治疗的基础上给予参芪化瘀解毒方。对比2组患者的治疗效果,化疗不良反应及治疗前、后生活质量。结果观察组治疗总有效率52.63%,高于对照组的28.94%(P<0.05);观察组化疗不良反应发生率23.68%,低于对照组的50.00%(P<0.05);2组治疗前卡氏评分无明显差异(P>0.05),治疗后观察组卡氏评分高于对照组(P<0.01)。结论参芪化瘀解毒方能有效提高手术联合TACE治疗原发性肝癌患者的治疗效果,并减轻化疗不良反应,提高患者生活质量。
Objective To analyze the role of Shenqi Huayu Jiedu Decoction in the treatment of patients with primary hepatocellular carcinoma by surgery combined with transcatheter arterial chemoembolization (TACE). Methods Totally 76 patients with primary liver cancer admitted to hospital were selected as study subjects and randomly divided into observation group and control group with 38 cases in each group. The control group was treated with liver cancer resection combined with TACE. The observation group was given Shenqi Huayu Jiedu Decoction on the basis of the control group. Comparison of two groups of patients with treatment, adverse reactions and chemotherapy before and after treatment, quality of life. Results The total effective rate of observation group was 52.63%, higher than that of control group (28.94%) (P <0.05). The adverse reaction rate of observation group was 23.68%, which was lower than that of control group (50.00%, P <0.05) There was no significant difference in Karnofsky scores (P> 0.05). After treatment, the Karnofstal score of the observation group was higher than that of the control group (P <0.01). Conclusion Shenqi Huayu Jiedu decoction can effectively improve the operation of TACE in the treatment of patients with primary liver cancer treatment, and reduce the adverse reactions of chemotherapy to improve the quality of life of patients.